

**Recombinant Human IGF-BP6**  
**Catalog # PBG10175****Specification**

---

**Recombinant Human IGF-BP6 - Product Information****Recombinant Human IGF-BP6 - Additional Information****Description**

IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6 is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid, and specifically inhibits IGF-II actions. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma. Recombinant human IGF-BP6 has a calculated mass of 22.6 kDa and consists of 213 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. IGF-BP6 migrates at an apparent molecular weight of approximately 23.0-30.0 kDa by SDS-PAGE analysis under non-reducing conditions.   
  
\*Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc.

**Biological Activity**

Determined by its ability to inhibit IGF-II induced proliferation of human MCF-7 cells. The expected  $ED_{50}$  for this effect is 0.1 - 0.4  $\mu$ g/ml.

**Authenticity**

Verified by N-terminal and Mass Spectrometry analyses (when applicable).

**Endotoxin**

Endotoxin level is  $<0.1$  ng/  $\mu$ g of protein ( $<1$ EU/  $\mu$ g).

**Protein Content**

Verified by UV Spectroscopy and/or SDS-PAGE gel.

**Storage**

-20°C

**Precautions**

Recombinant Human IGF-BP6 is for research use only and not for use in diagnostic or therapeutic procedures.

**Recombinant Human IGF-BP6 - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)

- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

## **Recombinant Human IGF-BP6 - Images**